Catalog No.S4248 Synonyms: AHR 10282R
Molecular Weight(MW): 356.15
Bromfenac Sodium is a nonsteroidal anti-inflammatory drug (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.
Purity & Quality Control
Choose Selective COX Inhibitors
|Description||Bromfenac Sodium is a nonsteroidal anti-inflammatory drug (NSAID), which has anti-inflammatory activity and may block prostaglandin synthesis by inhibiting cyclooxygenase 1 and 2.|
|In vivo||Bromfenac (bromfenac sodium) by the oral route at pretreatment times of 10 min, 20 min and 300 min is respectively 3.7, 6.5 and 2.9 times more potent than zomepirac and 3.4, 6.6, and 44.2 times more potent than suprofen in the acetylcholine abdominal constriction assay in mice. Bromfenac when given orally is 5.8 times more potent than zomepirac in blocking the nociceptive response to bradykinin in dogs. Bromfenac is 6.1 to 32.8 times more potent than indometacin in inhibiting the formation of prostaglandin E2 and F2 alpha from microsomes of bovine seminal vesicles, rabbit uteri, and rabbit renal medullae. Bromfenac, given orally, is more potent than indometacin in suppressing acute (7.5-20 times) and chronic (3.8 times) inflammation in mice.  Bromfenac (1 mg/kg, i.v.) is metabolited into an unusual conjugate, bromfenac N-glucoside, in rats bile.  Bromfenac shows a rapid onset of activity (20 min) that persisted for at least 4 hours in a mouse model of pain (acetylcholine abdominal constriction). Bromfenac (0.316 mg/kg) produces significant anti-inflammatory activity up to 24 hours after dosing in a rat model of inflammation (carrageenan foot edema). Bromfenac is readily absorbed after oral administration, peak plasma levels being achieved at the earliest time tested: 20 min in the mouse and 30 min in the rat. |
|In vitro||DMSO||71 mg/mL (199.35 mM)|
|Water||71 mg/mL (199.35 mM)|
|Ethanol||2 mg/mL (5.61 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02681679||Completed||Cataract||Sun Yat-sen University|Ministry of Health, China||October 2014||--|
|NCT02361645||Completed||Vitreous Inflammation||Università degli Studi di Brescia||March 2014||Phase 3|
|NCT02137161||Completed||Cataract|Pseudoexfoliation Syndrome||Arcispedale Santa Maria Nuova-IRCCS||November 2013||Phase 4|
|NCT01774474||Recruiting||Cystoid Macular Edema|Cataract|Diabetes Mellitus||Maastricht University Medical Center|European Society of Cataract and Refractive Surgeons||July 2013||Phase 3|
|NCT01847638||Recruiting||Cataract|Retinal Edema|Inflammation||Melissa Toyos, MD|Bausch & Lomb Incorporated|Discover Vision Centers||April 2013||--|
|NCT01475877||Completed||Myopia||Virdi Eye Clinic||May 2011||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.